Pharsight

Enstilar patents expiration

ENSTILAR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119781 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US10688108 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US10660908 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US9566286 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US10716799 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US10682364 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US10617698 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US10130640 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US9119781

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Dec, 2031

(8 years from now)

US10130640

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Dec, 2031

(8 years from now)

Enstilar is owned by Leo Pharma As.

Enstilar contains Betamethasone Dipropionate; Calcipotriene.

Enstilar has a total of 10 drug patents out of which 0 drug patents have expired.

Enstilar was authorised for market use on 16 October, 2015.

Enstilar is available in aerosol, foam;topical dosage forms.

Enstilar can be used as topical treatment of plaque psoriasis in patients 12 years and older, plaque psoriasis; topical treatment of plaque psoriasis in patients 12 years and older.

The generics of Enstilar are possible to be released after 10 December, 2031.

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity (PED) Jan 30, 2023

Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient

Market Authorisation Date: 16 October, 2015

Treatment: Plaque psoriasis; Topical treatment of plaque psoriasis in patients 12 years and older

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of ENSTILAR before it's drug patent expiration?
More Information on Dosage

ENSTILAR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic